{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:11:42Z","timestamp":1767849102696,"version":"3.49.0"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> There has been intensive research into enhancing the effects of reperfusion therapy to mitigate hemorrhagic transformation (HT) in stroke patients. Using neuroprotective agents alongside intravenous thrombolysis (IVT) appears a promising approach. Cerebrolysin is one of the candidates since it consists of neuropeptides mimicking the action of neurotrophic factors on brain protection and repair.<\/jats:p><jats:p><jats:bold>Objectives:<\/jats:bold> We looked at treatment effects of Cerebrolysin as an early add-on to IVT in stroke patients with varying HT risk.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> It was <jats:italic>post hoc<\/jats:italic> analysis of the CEREHETIS trial (<jats:ext-link>ISRCTN87656744<\/jats:ext-link>). Patients with middle cerebral artery infarction (<jats:italic>n<\/jats:italic> = 238) were selected from the intention-to-treat population. To stratify participants according to their HT risk, the DRAGON, SEDAN and HTI scores were computed for each eligible subject using on-admission data. The study endpoints were any and symptomatic HT, and functional outcome measured with the modified Rankin Scale (mRS) on day 90. Favorable functional outcome (FFO) was defined as an mRS \u22642. The performance of each stratification tool was estimated with regression approaches. Heterogeneous treatment effect analysis was conducted using techniques of meta-analysis and the matching-smoothing method.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The HTI score outperformed other tools in terms of HT risk stratification. Heterogeneity of Cerebrolysin treatment effects was moderate (I<jats:sup>2<\/jats:sup>, 35.8%\u201356.7%; H<jats:sup>2<\/jats:sup>, 1.56\u20132.31) and mild (I<jats:sup>2<\/jats:sup>, 10.9%; H<jats:sup>2<\/jats:sup>, 1.12) for symptomatic and any HT, respectively. A significant positive impact of Cerebrolysin on HT and functional outcome was observed in the moderate (HTI = 1) and high (HTI \u22652) HT risk patients, but it was neutral in those with the low (HTI = 0) risk. In particular, there was a steady decline in the rate of symptomatic (HTI = 0 vs. HTI = 4: by 4.3%, <jats:italic>p<\/jats:italic> = 0.077 vs. 21.1%, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) and any HT (HTI = 0 vs. HTI = 4: by 1.2%, <jats:italic>p<\/jats:italic> = 0.737 vs. 32.7%, <jats:italic>p<\/jats:italic> &amp;lt; 0.001). Likewise, an mRS score reduction (HTI = 0 vs. HTI = 4: by 1.8%, <jats:italic>p<\/jats:italic> = 0.903 vs. 126%, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) with a reciprocal increase of the fraction of FFO patients (HTI = 0 vs. HTI = 4: by 1.2% <jats:italic>p<\/jats:italic> = 0.757 vs. 35.5%, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) was found.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Clinically meaningful heterogeneity of Cerebrolysin treatment effects on HT and functional outcome was established in stroke patients. The beneficial effects were significant in those whose estimated on-admission HT risk was either moderate or high.<\/jats:p>","DOI":"10.3389\/fphar.2023.1288718","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T04:56:15Z","timestamp":1704430575000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Heterogeneous treatment effects of Cerebrolysin as an early add-on to reperfusion therapy: post hoc analysis of the CEREHETIS trial"],"prefix":"10.3389","volume":"14","author":[{"given":"Mikhail N.","family":"Kalinin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina R.","family":"Khasanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1590\/0004-282X-ANP-2021-0091","article-title":"Accuracy of predictive scores of hemorrhagic transformation in patients with acute ischemic stroke","volume":"80","author":"Andrade","year":"2022","journal-title":"Arq. Neuropsiquiatr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10654-021-00839-0","article-title":"Protecting against researcher bias in secondary data analysis: challenges and potential solutions","volume":"37","author":"Baldwin","year":"2022","journal-title":"Eur. J. Epidemiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1111\/ene.14936","article-title":"European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke","volume":"28","author":"Beghi","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"I","DOI":"10.1177\/2396987321989865","article-title":"European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke","volume":"6","author":"Berge","year":"2021","journal-title":"Eur. Stroke J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10072-017-3214-0","article-title":"Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials","volume":"39","author":"Bornstein","year":"2018","journal-title":"Neurol. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"CD008900","DOI":"10.1002\/14651858.CD008900.pub3","article-title":"Cerebrolysin for vascular dementia","volume":"2019","author":"Cui","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"694418","DOI":"10.3389\/fneur.2022.694418","article-title":"Endovascular treatment combined with standard medical treatment improves outcomes of posterior circulation stroke: a systematic review and meta-analysis","volume":"13","author":"Dong","year":"2022","journal-title":"Front. Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.jfma.2021.09.005","article-title":"Comparison of risk scores in predicting symptomatic intracerebral hemorrhage after endovascular thrombectomy","volume":"121","author":"Fu","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"key":"B11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1745-6215-10-43","article-title":"Dealing with heterogeneity of treatment effects: is the literature up to the challenge?","volume":"10","author":"Gabler","year":"2009","journal-title":"Trials"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1002\/psp4.12715","article-title":"Heterogeneous treatment effect analysis based on machine-learning methodology","volume":"10","author":"Gong","year":"2021","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3389\/fphar.2019.01245","article-title":"Cerebrolysin ameliorates focal cerebral ischemia injury through neuroinflammatory inhibition via CREB\/PGC-1\u03b1 pathway","volume":"10","author":"Guan","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1007\/s10072-017-3037-z","article-title":"Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials","volume":"38","author":"Guekht","year":"2017","journal-title":"Neurol. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","article-title":"Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke","volume":"359","author":"Hacke","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0140-6736(20)30258-0","article-title":"Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial","volume":"395","author":"Hill","year":"2020","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1056\/NEJMoa2213379","article-title":"Trial of endovascular therapy for acute ischemic stroke with large infarct","volume":"388","author":"Huo","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1214\/12-aoas593","article-title":"Estimating treatment effect heterogeneity in randomized program evaluation","volume":"7","author":"Imai","year":"2013","journal-title":"Ann. Appl. Stat."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/pan\/mpq035","article-title":"Estimation of heterogeneous treatment effects from randomized experiments, with application to the optimal planning of the get-out-the-vote campaign","volume":"19","author":"Imai","year":"2011","journal-title":"Polit. Anal."},{"key":"B20","volume-title":"Statistical software components S458346","author":"Jann","year":"2017"},{"key":"B21","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3390\/brainsci13030507","article-title":"Cerebrolysin in patients with TBI: systematic review and meta-analysis","volume":"13","author":"Jarosz","year":"2023","journal-title":"Brain Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12883-017-0958-3","article-title":"The hemorrhagic transformation index score: a prediction tool in middle cerebral artery ischemic stroke","volume":"17","author":"Kalinin","year":"2017","journal-title":"BMC Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.17116\/jnevro201911903224","article-title":"Kompleksnaia otsenka perfuzionnykh dannykh golovnogo mozga u bol\u2019nykh s ostrym ishemicheskim insul\u2019tom dlia prediktsii gemorragichesko\u012d transformatsii [A comprehensive assessment of brain perfusion data in patients with acute ischemic stroke for prediction of hemorrhagic transformation]","volume":"119","author":"Kalinin","year":"2019","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"B24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.expneurol.2006.01.032","article-title":"Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis","volume":"200","author":"Kelly","year":"2006","journal-title":"Exp. Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1001\/jama.2021.20956","article-title":"Heterogeneity of treatment effects in an analysis of pooled individual patient data from randomized trials of device closure of patent foramen ovale after stroke","volume":"326","author":"Kent","year":"2021","journal-title":"JAMA"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1161\/hs1001.096588","article-title":"Heterogeneity affecting outcome from acute stroke therapy: making reperfusion worse","volume":"32","author":"Kent","year":"2001","journal-title":"Stroke"},{"key":"B27","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1161\/STROKEAHA.119.027071","article-title":"Safety and outcomes of intravenous thrombolysis in posterior versus anterior circulation stroke: results from the safe implementation of treatments in stroke registry and meta-analysis","volume":"51","author":"Keselman","year":"2020","journal-title":"Stroke"},{"key":"B28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12883-023-03159-w","article-title":"Cerebrolysin as an early add-on to reperfusion therapy: risk of hemorrhagic transformation after ischemic stroke (CEREHETIS), a prospective, randomized, multicenter pilot study","volume":"23","author":"Khasanova","year":"2023","journal-title":"BMC Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e2311768","DOI":"10.1001\/jamanetworkopen.2023.11768","article-title":"Endovascular therapy for stroke presenting beyond 24 hours: a systematic review and meta-analysis","volume":"6","author":"Kobeissi","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"B30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1747-4949.2012.00901.x","article-title":"A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke","volume":"8","author":"Lang","year":"2013","journal-title":"Int. J. Stroke"},{"key":"B31","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000047659","article-title":"Differences between anterior and posterior circulation stroke in TOAST","volume":"11","author":"Libman","year":"2001","journal-title":"Cerebrovasc. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1136\/neurintsurg-2021-017667","article-title":"Endovascular thrombectomy without versus with intravenous thrombolysis in acute ischemic stroke: a non-inferiority meta-analysis of randomized clinical trials","volume":"14","author":"Lin","year":"2022","journal-title":"J. Neurointerv Surg."},{"key":"B33","doi-asserted-by":"publisher","first-page":"104256","DOI":"10.1016\/j.jbi.2022.104256","article-title":"Emulate randomized clinical trials using heterogeneous treatment effect estimation for personalized treatments: methodology review and benchmark","volume":"137","author":"Ling","year":"2023","journal-title":"J. Biomed. Inf."},{"key":"B34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3389\/fneur.2018.00301","article-title":"Reperfusion and clinical outcomes in acute ischemic stroke: systematic review and meta-analysis of the stent-retriever-based, early window endovascular stroke trials","volume":"9","author":"Manning","year":"2018","journal-title":"Front. Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1358\/dot.2012.48(Suppl.A).1739716","article-title":"The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders","volume":"48","author":"Masliah","year":"2012","journal-title":"Drugs Today (Barc)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"g3175","DOI":"10.1136\/bmj.g3175","article-title":"Posterior circulation ischaemic stroke","volume":"348","author":"Merwick","year":"2014","journal-title":"BMJ"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1161\/01.str.0000018684.86293.ab","article-title":"Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design","volume":"33","author":"Muir","year":"2002","journal-title":"Stroke"},{"key":"B38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ahj.2023.02.015","article-title":"Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning method","volume":"260","author":"Ngufor","year":"2023","journal-title":"Am. Heart J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"117217","DOI":"10.1016\/j.jns.2020.117217","article-title":"Strategies to prevent hemorrhagic transformation after reperfusion therapies for acute ischemic stroke: a literature review","volume":"419","author":"Otsu","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"106767","DOI":"10.1016\/j.clineuro.2021.106767","article-title":"Efficacy and safety of Cerebrolysin after futile recanalisation therapy in patients with severe stroke","volume":"207","author":"Poljakovic","year":"2021","journal-title":"Clin. Neurol. Neurosurg."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American heart association\/American stroke association","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"key":"B42","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.annepidem.2021.07.003","article-title":"Generalizability of heterogeneous treatment effects based on causal forests applied to two randomized clinical trials of intensive glycemic control","volume":"65","author":"Raghavan","year":"2022","journal-title":"Ann. Epidemiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1161\/01.str.32.3.669","article-title":"Have randomized controlled trials of neuroprotective drugs been underpowered? An illustration of three statistical principles","volume":"32","author":"Samsa","year":"2001","journal-title":"Stroke"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1161\/STROKEAHA.110.607614","article-title":"Outcomes of intravenous thrombolysis in posterior versus anterior circulation stroke","volume":"42","author":"Sarikaya","year":"2011","journal-title":"Stroke"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1056\/NEJMoa2214403","article-title":"Trial of endovascular thrombectomy for large ischemic strokes","volume":"388","author":"Sarraj","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.wneu.2023.05.033","article-title":"Endovascular thrombectomy versus endovascular thrombectomy preceded by intravenous thrombolysis: a systematic review and meta-analysis","volume":"177","author":"Sattari","year":"2023","journal-title":"World Neurosurg."},{"key":"B47","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1538-7836.2011.04371.x","article-title":"Improving reperfusion therapy for acute ischaemic stroke","volume":"9","author":"Saver","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.3390\/life13101965","article-title":"Comprehensive meta-analysis of futile recanalization in acute ischemic stroke patients undergoing endovascular thrombectomy: prevalence, factors, and clinical outcomes","volume":"13","author":"Shen","year":"2023","journal-title":"Life (Basel)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"h1302","DOI":"10.1136\/bmj.h1302","article-title":"Precision medicine to improve use of bleeding avoidance strategies and reduce bleeding in patients undergoing percutaneous coronary intervention: prospective cohort study before and after implementation of personalized bleeding risks","volume":"350","author":"Spertus","year":"2015","journal-title":"BMJ"},{"key":"B50","doi-asserted-by":"publisher","first-page":"661955","DOI":"10.3389\/fneur.2021.661955","article-title":"Hemorrhagic transformation in ischemic stroke and the role of inflammation","volume":"12","author":"Spronk","year":"2021","journal-title":"Front. Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"910697","DOI":"10.3389\/fneur.2022.910697","article-title":"Efficacy of cerebrolysin treatment as an add-on therapy to mechanical thrombectomy in patients with acute ischemic stroke due to large vessel occlusion: study protocol for a prospective, open label, single-center study with 12 Months of follow-up","volume":"13","author":"Staszewski","year":"2022","journal-title":"Front. Neurol."},{"key":"B52","article-title":"Stata meta-analysis reference manual","volume-title":"Stata: release 17. Statistical software","year":"2021"},{"key":"B53","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/ana.23546","article-title":"Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score","volume":"71","author":"Strbian","year":"","journal-title":"Ann. Neurol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.0b013e318245d2a9","article-title":"Predicting outcome of IV thrombolysis-treated ischemic stroke patients: the DRAGON score","volume":"78","author":"Strbian","year":"","journal-title":"Neurology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1239953","DOI":"10.3389\/fneur.2023.1239953","article-title":"Intravenous thrombolysis and endovascular therapy for acute ischemic stroke in COVID-19: a systematic review and meta-analysis","volume":"14","author":"Stuckart","year":"2023","journal-title":"Front. Neurol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1079205","DOI":"10.3389\/fneur.2023.1079205","article-title":"Risk factors of hemorrhagic transformation in acute ischaemic stroke: a systematic review and meta-analysis","volume":"14","author":"Sun","year":"2023","journal-title":"Front. Neurol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jns.2013.08.036","article-title":"Predicting symptomatic intracerebral hemorrhage after intravenous thrombolysis: stroke territory as a potential pitfall","volume":"335","author":"Sung","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/WNR.0000000000001598","article-title":"Therapeutic effect of Cerebrolysin on reducing impaired cerebral endothelial cell permeability","volume":"32","author":"Teng","year":"2021","journal-title":"Neuroreport"},{"key":"B58","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/978-3-7091-6781-6_29","article-title":"Neurotrophic effects of Cerebrolysin in animal models of excitotoxicity","volume":"59","author":"Veinbergs","year":"2000","journal-title":"J. Neural Transm. Suppl."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1161\/01.STR.0000143219.16695.af","article-title":"Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke","volume":"35","author":"Wang","year":"2004","journal-title":"Stroke"},{"key":"B60","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/s13063-020-04306-1","article-title":"Graphing and reporting heterogeneous treatment effects through reference classes","volume":"21","author":"Watson","year":"2020","journal-title":"Trials"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1161\/STROKEAHA.112.665331","article-title":"Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies","volume":"43","author":"Whiteley","year":"2012","journal-title":"Stroke"},{"key":"B62","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1177\/1536867x0600600104","article-title":"Generalized ordered logit\/partial proportional odds models for ordinal dependent variables","volume":"6","author":"Williams","year":"2006","journal-title":"Stata J."},{"key":"B63","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1177\/0081175012452652","article-title":"Estimating heterogeneous treatment effects with observational data","volume":"42","author":"Xie","year":"2012","journal-title":"Sociol. Methodol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/svn-2022-001740","article-title":"Endovascular treatment for basilar artery occlusion: a meta-analysis","volume":"8","author":"Xu","year":"2023","journal-title":"Stroke Vasc. Neurol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1056\/NEJMoa2118191","article-title":"Endovascular therapy for acute stroke with a large ischemic region","volume":"386","author":"Yoshimura","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1002\/jnr.22495","article-title":"Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke","volume":"88","author":"Zhang","year":"2010","journal-title":"J. Neurosci. Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1161\/STROKEAHA.121.035267","article-title":"Effect of occlusion site on the safety and efficacy of intravenous alteplase before endovascular thrombectomy: a prespecified subgroup analysis of DIRECT-MT","volume":"53","author":"Zhou","year":"2022","journal-title":"Stroke"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1096153","DOI":"10.3389\/fneur.2023.1096153","article-title":"Analyzing and predicting the risk of death in stroke patients using machine learning","volume":"14","author":"Zhu","year":"2023","journal-title":"Front. Neurol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"CD007026","DOI":"10.1002\/14651858.CD007026.pub7","article-title":"Cerebrolysin for acute ischaemic stroke","volume":"10","author":"Ziganshina","year":"2023","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1288718\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T04:56:30Z","timestamp":1704430590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1288718\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":68,"alternative-id":["10.3389\/fphar.2023.1288718"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1288718","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,5]]},"article-number":"1288718"}}